The Aryl Hydrocarbon Receptor As a Tumor Modulator: Mechanisms to Therapy

Overview

Journal Front Oncol

Specialty Oncology

Date 2024 May 29

PMID 38807762

Authors

Kanita A Chaudhry

Anna Bianchi-Smiraglia

Affiliations

Soon will be listed here.

Abstract

The aryl hydrocarbon receptor (AhR) is a ligand-activated transcription factor that is widely recognized to play important, but complex, modulatory roles in a variety of tumor types. In this review, we comprehensively summarize the increasingly controversial role of AhR as a tumor regulator and the mechanisms by which it alters tumor progression based on the cancer cell type. Finally, we discuss new and emerging strategies to therapeutically modulate AhR, focusing on novel agents that hold promise in current human clinical trials as well as existing FDA-approved drugs that could potentially be repurposed for cancer therapy.

Citing Articles

Unveiling the Immune effects of AHR in tumors: a decade of insights from bibliometric analysis (2010-2023).

Xie A, Wang T, Shi W, He F, Sun X, Li P Discov Oncol. 2024; 15(1):616.

PMID: 39495340 PMC: 11535112. DOI: 10.1007/s12672-024-01480-5.

Vulnerability of Antioxidant Drug Therapies on Targeting the Nrf2-Trp53-Jdp2 Axis in Controlling Tumorigenesis.

Lin Y, Ku C, Wuputra K, Wu D, Yokoyama K Cells. 2024; 13(19.

PMID: 39404411 PMC: 11475825. DOI: 10.3390/cells13191648.

A reference for selecting an appropriate method for generating glioblastoma organoids from the application perspective.

Liang J, He P Discov Oncol. 2024; 15(1):459.

PMID: 39292297 PMC: 11411047. DOI: 10.1007/s12672-024-01346-w.

References

Wilson S, Joshi A, Elferink C . The tumor suppressor Kruppel-like factor 6 is a novel aryl hydrocarbon receptor DNA binding partner. J Pharmacol Exp Ther. 2013; 345(3):419-29. PMC: 3657114. DOI: 10.1124/jpet.113.203786. View

Fritz W, Lin T, Cardiff R, Peterson R . The aryl hydrocarbon receptor inhibits prostate carcinogenesis in TRAMP mice. Carcinogenesis. 2006; 28(2):497-505. DOI: 10.1093/carcin/bgl179. View

Chen X, Zang Y, Li D, Guo J, Wang Y, Lin Y . IDO, TDO, and AHR overexpression is associated with poor outcome in diffuse large B-cell lymphoma patients in the rituximab era. Medicine (Baltimore). 2020; 99(21):e19883. PMC: 7249864. DOI: 10.1097/MD.0000000000019883. View

Beischlag T, Perdew G . ER alpha-AHR-ARNT protein-protein interactions mediate estradiol-dependent transrepression of dioxin-inducible gene transcription. J Biol Chem. 2005; 280(22):21607-11. DOI: 10.1074/jbc.C500090200. View

Yu C, Rao D, Zhu H, Liu Q, Huang W, Zhang L . TDO2 Was Downregulated in Hepatocellular Carcinoma and Inhibited Cell Proliferation by Upregulating the Expression of p21 and p27. Biomed Res Int. 2021; 2021:4708439. PMC: 8378971. DOI: 10.1155/2021/4708439. View

Kober C, Roewe J, Schmees N, Roese L, Roehn U, Bader B . Targeting the aryl hydrocarbon receptor (AhR) with BAY 2416964: a selective small molecule inhibitor for cancer immunotherapy. J Immunother Cancer. 2023; 11(11). PMC: 10649913. DOI: 10.1136/jitc-2023-007495. View

Kim D, Gazourian L, Quadri S, Romieu-Mourez R, Sherr D, Sonenshein G . The RelA NF-kappaB subunit and the aryl hydrocarbon receptor (AhR) cooperate to transactivate the c-myc promoter in mammary cells. Oncogene. 2000; 19(48):5498-506. DOI: 10.1038/sj.onc.1203945. View

Song J, Clagett-Dame M, Peterson R, Hahn M, Westler W, Sicinski R . A ligand for the aryl hydrocarbon receptor isolated from lung. Proc Natl Acad Sci U S A. 2002; 99(23):14694-9. PMC: 137481. DOI: 10.1073/pnas.232562899. View

Koliopanos A, Kleeff J, Xiao Y, Safe S, Zimmermann A, Buchler M . Increased arylhydrocarbon receptor expression offers a potential therapeutic target for pancreatic cancer. Oncogene. 2002; 21(39):6059-70. DOI: 10.1038/sj.onc.1205633. View

10.

Stanford E, Wang Z, Novikov O, Mulas F, Landesman-Bollag E, Monti S . The role of the aryl hydrocarbon receptor in the development of cells with the molecular and functional characteristics of cancer stem-like cells. BMC Biol. 2016; 14:20. PMC: 4794823. DOI: 10.1186/s12915-016-0240-y. View

11.

Li L, Wang T, Li S, Chen Z, Wu J, Cao W . TDO2 Promotes the EMT of Hepatocellular Carcinoma Through Kyn-AhR Pathway. Front Oncol. 2021; 10:562823. PMC: 7851084. DOI: 10.3389/fonc.2020.562823. View

12.

ODonnell E, Koch D, Bisson W, Jang H, Kolluri S . The aryl hydrocarbon receptor mediates raloxifene-induced apoptosis in estrogen receptor-negative hepatoma and breast cancer cells. Cell Death Dis. 2014; 5:e1038. PMC: 4040680. DOI: 10.1038/cddis.2013.549. View

13.

Tarnow P, Tralau T, Luch A . Chemical activation of estrogen and aryl hydrocarbon receptor signaling pathways and their interaction in toxicology and metabolism. Expert Opin Drug Metab Toxicol. 2019; 15(3):219-229. DOI: 10.1080/17425255.2019.1569627. View

14.

Chen Z, Cai A, Zheng H, Huang H, Sun R, Cui X . Carbidopa suppresses prostate cancer via aryl hydrocarbon receptor-mediated ubiquitination and degradation of androgen receptor. Oncogenesis. 2020; 9(5):49. PMC: 7220950. DOI: 10.1038/s41389-020-0236-x. View

15.

DAmato N, Rogers T, Gordon M, Greene L, Cochrane D, Spoelstra N . A TDO2-AhR signaling axis facilitates anoikis resistance and metastasis in triple-negative breast cancer. Cancer Res. 2015; 75(21):4651-64. PMC: 4631670. DOI: 10.1158/0008-5472.CAN-15-2011. View

16.

Nebert D, Roe A, Dieter M, Solis W, Yang Y, Dalton T . Role of the aromatic hydrocarbon receptor and [Ah] gene battery in the oxidative stress response, cell cycle control, and apoptosis. Biochem Pharmacol. 1999; 59(1):65-85. DOI: 10.1016/s0006-2952(99)00310-x. View

17.

Miyazaki T, Chung S, Sakai H, Ohata H, Obata Y, Shiokawa D . Stemness and immune evasion conferred by the TDO2-AHR pathway are associated with liver metastasis of colon cancer. Cancer Sci. 2021; 113(1):170-181. PMC: 8748246. DOI: 10.1111/cas.15182. View

18.

Moennikes O, Loeppen S, Buchmann A, Andersson P, Ittrich C, Poellinger L . A constitutively active dioxin/aryl hydrocarbon receptor promotes hepatocarcinogenesis in mice. Cancer Res. 2004; 64(14):4707-10. DOI: 10.1158/0008-5472.CAN-03-0875. View

19.

Ye M, Zhang Y, Gao H, Xu Y, Jing P, Wu J . Activation of the Aryl Hydrocarbon Receptor Leads to Resistance to EGFR TKIs in Non-Small Cell Lung Cancer by Activating Src-mediated Bypass Signaling. Clin Cancer Res. 2017; 24(5):1227-1239. DOI: 10.1158/1078-0432.CCR-17-0396. View

20.

Zhu P, Yu H, Zhou K, Bai Y, Qi R, Zhang S . 3,3'-Diindolylmethane modulates aryl hydrocarbon receptor of esophageal squamous cell carcinoma to reverse epithelial-mesenchymal transition through repressing RhoA/ROCK1-mediated COX2/PGE pathway. J Exp Clin Cancer Res. 2020; 39(1):113. PMC: 7298755. DOI: 10.1186/s13046-020-01618-7. View